Processing

Please wait...

Settings

Settings

1. WO2020006349 - THERAPEUTIC LUNG REPAIR BY INHALATION OF LUNG SPHEROID CELL-SECRETED FACTORS

Publication Number WO/2020/006349
Publication Date 02.01.2020
International Application No. PCT/US2019/039721
International Filing Date 28.06.2019
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
12
Materials from mammals or birds
42
Lungs
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
A61K 35/42 (2015.01)
C12N 5/071 (2010.01)
CPC
A61K 35/42
Applicants
  • NORTH CAROLINA STATE UNIVERSITY [US/US]; Office of Research Commercialization 1021 Main Campus Drive, 2nd Floor Raleigh, North Carolina 27606, US
Inventors
  • CHENG, Ke; US
  • DINH, Phuong-Uyen; US
Agents
  • HAYZER, David, J.; THOMAS HORSTEMEYER LLP 3200 Windy Hill Road SE Suite 1600E Atlanta, Georgia 30339, US
Priority Data
62/691,81129.06.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) THERAPEUTIC LUNG REPAIR BY INHALATION OF LUNG SPHEROID CELL-SECRETED FACTORS
(FR) RÉPARATION PULMONAIRE THÉRAPEUTIQUE PAR INHALATION DE FACTEURS SÉCRÉTÉS DE CELLULES SPHÉROÏDES PULMONAIRES
Abstract
(EN)
Idiopathic pulmonary fibrosis (IPF) is currently the most fatal form of idiopathic interstitial lung disease in which persistent lung injuries result in scar tissue formation. Provided are methods and compositions for the treatment of pulmonary conditions such as fibrosis. Lung spheroid cell-derived conditioned media (LSC-CM) and exosomes (LSC-EXO) are used to treat different models of lung injury. Inhalation treatment with LSC-CM and LSC-EXO-derived compositions can attenuate and/or reverse bleomycin- and silica-induced fibrosis, reestablish normal alveolar structure and decrease extracellular matrix accumulation.
(FR)
La fibrose pulmonaire idiopathique (FPI) est actuellement la forme la plus fatale de maladie pulmonaire interstitielle idiopathique avec laquelle des lésions pulmonaires persistantes entraînent la formation de tissus cicatriciels. L'invention concerne des procédés et des compositions pour le traitement de maladies pulmonaires telles que la fibrose. Des milieux conditionnés dérivés de cellules sphéroïdes pulmonaires (LSC-CM) et des exosomes (LSC-EXO) sont utilisés pour traiter différents modèles de lésion pulmonaire. Un traitement par inhalation avec des compositions dérivées de LSC-CM et de LSC-EXO peut atténuer et/ou inverser la fibrose induite par la bléomycine et la silice, rétablir la structure alvéolaire normale et diminuer l'accumulation de la matrice extracellulaire.
Latest bibliographic data on file with the International Bureau